Advances in stem cell technologies have created a robust market for stem cell products and platforms targeted at researchers, manufacturers, and patients.
In its entirety, the stem cell products industry encompasses stem cells and derived products, processing materials and equipment, as well as adjunct services and products enabling stem cell technologies. While the core of the stem cell products market is composed of stem cell lines and related cell-based products, adjunct technologies that impact these products also contribute market share.
Categories of Products Related to Stem Cell Research
The complexity of stem cell technologies has led to substantial market diversity, as well as increased collaboration between various market entities and sectors. Categories of products related to stem cell research include:
- Cell Lines
- Culture and Maintenance Products
- Growth Factors and Cytokines
- Characterization Services
- Primary Antibodies
- Fluorescent- and Bead-Based Analytical Tools
- Molecular Tools for Gene Regulation
- RNA and Protein Purification
- Imaging and Tracking Systems
- And More
These stem cell products can be sold as stand-alone products, product bundles, or as fully functional kits designed to facilitate each step of the research process.
Funding to Support the Development of Stem Cell Products
Within the U.S., the National Institutes of Health (NIH) will invest an estimated $1.495 billion into stem cell research projects in 2016, spanning a wide range of fields from cell biology to electrical engineering.1
This is an increase from $1.391 billion in (actual) spending by the NIH in 2014 and $1,429 billion in (estimated) spending by the NIH in 2015.
Several state programs made additional contributions to stem cell research projects, the largest being the California Institute of Regenerative Medicine (CIRM), who awarded over $126 million worth of funding in 2014.2
Internationally, stem cell research is supported by significant government investments, and the pharmaceutical industry and private sources contributed over $1.7 billion dollars of funding on a global basis during full-year 2015.3
Trends in Stem Cell Product Development
Though adult stem cell therapy products are available throughout much of the developed and developing world, pluripotent stem cell-based therapies (those derived from iPS cells and ESCs) remain largely in preclinical or early clinical development.
Therefore, the stem cell industry has been heavily propelled by the development and manufacture of stem cell research products, although this is gradually shifting as pluripotent stem cell therapies move closer to the clinic. The market for stem cell research tools, including cells, kits, and consumables, has also grown significantly over the past few years to include a wide variety of products.
Therefore, the number of life science companies offering stem cell research products has multiplied from only a couple dozen companies in 2006 to several hundred companies today.
This growth has been largely attributed to increasing acceptance of stem cell technologies, most notably stem cell applications to treat chronic disease and recognition of the potential for regenerative medicine to reduce globally escalating healthcare costs.4
Rising healthcare costs are one of the key factors driving investment into stem cell products and therapies within Japan, with Japan’s Education Ministry stating that it plans to spend 110 billion yen ($1.13 billion) on induced pluripotent stem cell research during the next 10 years. The Japanese parliament has also been discussing bills that would “speed the approval process and ensure the safety of such treatments.
Recently, stem cell market segments that support clinical development – for example, stem cell banking, stem cell expansion, and stem cell manufacturing – have been become fast-growth segments.
Market Leaders Driving Stem Cell Product Trends
Companies operating in the stem cell space range from small entities specializing in a single product to large international conglomerates, such as Thermo Fisher Scientific (NYSE: TMO), BD Biosciences (NYSE:BDX) and Miltenyi Biotec (Bergisch Gladbach, Germany). Led by these market leaders, BioInformant’s analysis of stem cell-based research products has valued the current market for stem cell research products at over USD $2 billion.
To learn more, view “Stem Cell Research Products – Opportunities, Tools, and Technologies.”
BioInformant is the firt and only market research firm to specialize in the stem cell industry. Our research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Xconomy, and Vogue Magazine. Serving industry leaders that include GE Healthcare, Pfizer, Goldman Sachs, and Becton Dickinson, BioInformant is your global leader in stem cell industry data.
1 Report.nih.gov,. “NIH Categorical Spending -NIH Research Portfolio Online Reporting Tools (Report)”. N.p., 2016. Web. 18 Jan. 2016.
2 California’s Stem Cell Agency,. “CIRM Funding Commitments”. N.p., 2009. Web. 18 Jan. 2016.
3 BioInformant.com,. “Stem Cell Research Products – Opportunities, Tools, & Technologies”. N.p., 2016. Web. 21 Feb. 2016.
4 Biomedtrends.com,. “Biomedtrends”. N.p., 2016. Web. 18 Jan. 2016.